{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "d0c467fe-879d-4c68-8a94-d48309a97974",
   "metadata": {},
   "outputs": [],
   "source": [
    "with open('tp201587a.txt') as f:\n",
    "        text = f.readlines()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dab12588-a34f-4ce9-b292-6f37f2c85769",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Input strings: ['OPEN', 'ORIGINAL ARTICLE', 'Modiﬁcations of the endosomal compartment in peripheral', 'blood mononuclear cells and ﬁbroblasts from Alzheimer’s', 'disease patients', 'F Corlier1,2,3, I Rivals4, J Lagarde5, L Hamelin5, H Corne5, L Dauphinot1,2,3, K Ando1,2,3, J-C Cossec1,2,3, G Fontaine1,2,3, G Dorothée6,7,', 'C Malaplate-Armand8,9, J-L Olivier8,9, B Dubois10, M Bottlaender11, C Duyckaerts1,2,3,12, M Sarazin5,13, M-C Potier1,2,3,13 and the Clinical', 'ImaBio3 team14', 'Identiﬁcation of blood-based biomarkers of Alzheimer’s disease (AD) remains a challenge. Neuropathological studies have', 'identiﬁed enlarged endosomes in post-mortem brains as the earliest cellular change associated to AD. Here the presence of', 'enlarged endosomes was investigated in peripheral blood mononuclear cells from 48 biologically deﬁned AD patients (25 with mild', 'cognitive impairment and 23 with dementia (AD-D)), and 23 age-matched healthy controls using immunocytochemistry and', 'confocal microscopy. The volume and number of endosomes were not signiﬁcantly different between AD and controls. However,', 'the percentage of cells containing enlarged endosomes was signiﬁcantly higher in the AD-D group as compared with controls.', 'Furthermore, endosomal volumes signiﬁcantly correlated to [C11]PiB cortical index measured by positron emission tomography in', 'the AD group, independently of the APOE genotype, but not to the levels of amyloid-beta, tau and phosphorylated tau measured in', 'the cerebrospinal ﬂuid. Importantly, we conﬁrmed the presence of enlarged endosomes in ﬁbroblasts from six unrelated AD-D', 'patients as compared with ﬁve cognitively normal controls. This study is the ﬁrst, to our knowledge, to report morphological', 'alterations of the endosomal compartment in peripheral cells from AD patients correlated to amyloid load that will now be', 'evaluated as a possible biomarker.', 'Translational Psychiatry (2015) 5, e595; doi:10.1038/tp.2015.87; published online 7 July 2015', 'INTRODUCTION', 'An estimated 35 million people worldwide suffer from dementia,', 'and this number, predicted to double every 20 years, will rise to', 'more than 65 million in 2030 and more than 115 million in 2050.1', 'Alzheimer’s disease (AD) is the most common cause of dementia.', 'New proposals for the diagnosis of AD combine clinical tools and', 'biological markers such as cerebrospinal ﬂuid (CSF) biomarkers', 'and amyloid positron emission tomography (PET) imaging for', 'identifying the underlying AD pathophysiological process. This', 'approach allows establishing a clinical diagnosis of AD at the stage', 'of mild cognitive impairment (MCI), before dementia, but needs', 'invasive and expansive tools.2', 'Autopsy still remains the only fully reliable diagnosis. AD', 'is neuropathologically characterized by extracellular amyloid', 'plaques composed of β-amyloid peptides (Aβ) and intracellular', 'neuroﬁbrillary tangles constituted of hyperphosphorylated tau', 'protein.3 Although the degree of tauopathy correlates strongly', 'with cognitive decline in AD, the aggregation of Aβ has a critical', 'role as early trigger, and recent longitudinal PET imaging studies', 'indicated that cerebral Aβ deposition precedes the clinical', 'symptoms of AD by a decade or more.4,5', 'One of the main challenges associated with the diagnosis of AD', 'is the identiﬁcation and validation of blood-based biomarkers.', 'Among different tracks, neuropathological and clinical data', 'suggested the presence of enlarged endosomes as a candidate', 'cellular biomarker in the blood.', 'Indeed dysregulation of the endolysosomal compartment has', 'been found in the brain of AD patients.6,7 Neurons bearing', 'enlarged endosomes were identiﬁed as the earliest morphological', 'change observed in post-mortem brains from patients with', 'sporadic AD before the onset of clinical symptoms.8,9 Although', 'familial AD cases with mutations in the amyloid precursor protein', 'gene harboured the same endosomal phenotype, cases with', 'mutations in the presenilin genes did not.10 Enlarged endosomes', 'were also observed in individuals with Down syndrome (DS) who', 'are at high risk for AD (45% of DS people have AD at 60 years', '1UPMC University Paris 06, UMRS 1127, Sorbonne Universités, Paris, France; 2INSERM U 1127, Paris, France; 3ICM Research Centre, CNRS UMR 7225, Paris, France; 4Équipe de', 'Statistique Appliquée, ESPCI ParisTech, PSL Research University, INSERM UMRS 1158, Paris, France; 5Neurologie de la Mémoire et du Langage, Service de Neurologie, Université', 'Paris Descartes, Sorbonne Paris Cité, INSERM UMR S894, Centre Hospitalier Sainte Anne, Paris, France; 6INSERM UMRS 938, Laboratoire Système Immunitaire et Maladies', 'Conformationnelles, Hôpital Saint-Antoine, Paris, France; 7Université Pierre et Marie Curie, Université Paris 6, Centre de Recherche Saint-Antoine, Hôpital Saint-Antoine, Paris,', 'France; 8Laboratoire de Biochimie et Biologie Moléculaire, UF Oncologie—Endocrinologie—Neurobiologie, Hôpital Central, Centre Hospitalier Universitaire, Nancy, France; 9UR', 'AFPA—USC 340, Equipe BFLA, Université de Lorraine, Nancy, France; 10Institut de la mémoire et de la maladie d’Alzheimer, IMMA, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris,', 'France; 11CEA (MB), DSV, Institut d’Imagerie Biomédicale, Service Hospitalier Frédéric Joliot, Orsay, France and 12Laboratoire de Neuropathologie Escourolle, Hôpital de la Pitié-', \"Salpêtrière, AP-HP, Paris, France. Correspondence: Dr M-C Potier, ICM Research Centre, Group of Alzheimer's and Prion's diseases, CNRS UMR7225, INSERM URM975, UPMC,\", \"Hôpital de la Pitié-Salpêtrière, 47 Boulevard de l'Hôpital, 75013 Paris, France.\", 'E-mail: marie-claude.potier@upmc.fr', '13These two authors contributed equally to this work.', '14Members of the Clinical ImaBio3 team are listed before References.', 'Received 23 February 2015; accepted 21 May 2015', 'Citation: Transl Psychiatry (2015) 5, e595; doi:10.1038/tp.2015.87', 'www.nature.com/tp', 'against ~ 3% in the general population).11 In DS, enlarged', 'endosomes have been identiﬁed not only in neuronal cells but', 'also in peripheral cells such as peripheral blood mononuclear cells', '(PBMCs), lymphoblastoids and ﬁbroblasts.12,13', 'AD genome-wide association studies suggest a crucial role of', 'several proteins involved in membrane trafﬁcking such as PICALM,', 'SORL1, BIN1.14 In addition, several endolysosomal proteins such as', 'EEA1, Rab3, Rab7, LAMP1 and LAMP2 were found increased in the', 'CSF of AD patients.15 These data suggest that endosomal', 'dysmorphologies could be associated with amyloid pathology in', 'AD and could thus be detected in blood cells from AD patients at', 'an early stage of the disease.', 'In this study, we applied the immunocytochemical method that', 'we developed earlier for analysing the endosomal compartment', 'of PBMCs from DS patients13 to isolated PBMCs from 48', 'biologically conﬁrmed AD patients (25 with mild cognitive', 'impairment (AD-MCI) and 23 at the dementia stage (AD-D)) and', '23 cognitively normal controls, with no evidence of preclinical AD', '(negative for the amyloid imaging). Results were conﬁrmed in', 'ﬁbroblasts from six independent AD-D patients and ﬁve cogni-', 'tively normal controls. We hypothesised that the endosomes in', 'cells from AD would be different from controls, even at the', 'MCI stage.', 'MATERIALS AND METHODS', 'Participants', 'PBMCs were analysed from 71 subjects, enrolled in the ImaBio3 study (NCT:', 'NCT01775696). Forty-eight AD patients with biologically conﬁrmed AD', 'were included according to the following criteria: (1) predominant and', 'progressive episodic memory impairment, characterized by low free recall', 'not normalized with cueing (free recall 419/48 and total recall o41/48', 'in the Free and Cued Selective Reminding Test, FCSRT), associated or not', 'with', 'other', 'cognitive', 'impairments;', '(2)', 'biological', 'evidence', 'of', 'AD', 'pathophysiological process as deﬁned by CSF AD biomarker proﬁle', 'and/or signiﬁcant amyloid retention on PET with [C11]- labelled Pittsburgh', 'Compound B ([C11]PiB). A CSF AD biomarker proﬁle was deﬁned as score', 'o0.8 for the ratio of Aβ 42/tau, calculated with the formula Aβ 42/[240', '+(1.18 × total tau)].16 Signiﬁcant ﬁxation of [C11]PiB on PET was deﬁned by', 'a global cortical index higher than 1.4.17 We excluded subjects who had', 'clinical or neuroimaging evidence of focal lesions, severe cortical or', 'subcortical vascular lesions on magnetic resonance imaging and severe', 'depression.', 'Patients were stratiﬁed according to disease severity assessed by the', 'Clinical Dementia Rating scale (CDR): 25 patients had a score of 0.5', 'representing AD-MCI with isolated episodic memory impairments and only', 'moderated impact on the activities of daily living, and 23 patients had a', 'CDR scale score 40.5 representing AD-D.', 'Twenty-three healthy elderly control subjects were selected according', 'to the following criteria: (1) MMSE (Mini Mental State Examination) ⩾ 27', 'and normal neuropsychological testing; (2) no history of psychiatric or', 'neurologic conditions, (3) no evidence of focal lesion or severe cortical or', 'subcortical vascular lesions on magnetic resonance imaging.', 'To improve diagnostic accuracy, all the subjects had at least one 12-', 'month follow-up to validate the AD diagnosis according to their clinical', 'evolution, or the absence of cognitive decline for controls.', 'The study was conducted by the Assistance Publique des Hôpitaux de', 'Paris (PHRC-0053-N) and was approved by the Ethics Committee of Pitié-', 'Salpêtrière Hospital. All the subjects provided written, informed consent', 'before participating.', 'Analysis of ﬁbroblasts', 'Fibroblasts were obtained independently from a regional PHRC (Projet', 'Hospitalier de Recherche Clinique) in 2003 coordinated by the Centre', 'Hospitalo-Universitaire of Nancy (France). Eleven additional participants', 'without a known family history of AD were enrolled: six patients with', 'sporadic AD-D (mean age: 78.5 ± 7.77, MMSE o25) and ﬁve healthy', 'volunteers (mean age: 70.8 ± 8.01, MMSE = 30). Skin biopsies taken from', 'the upper arm were explanted and grown in DMEM-glutamax supple-', 'mented with 10% fetal bovine serum, 100 units ml − 1 penicillin and 100 -', 'μg ml − 1 streptomycin (Gibco BRL, Life Technologies, Saint Aubin, France,', 'European Division) at 37 °C in humidiﬁed air with 5% CO2. Experiments on', 'AD and control ﬁbroblasts were performed at the same stage of doubling', 'in culture (o12 passages).', 'Participants were selected in accordance with local ethic recommenda-', 'tions: CCPPRB (Comité Consultatif de Protection des Personnes dans la', 'Recherche Biomédicale) de Lorraine n° 04-03-01.', 'For both groups, all the subjects provided written informed consent', 'before participating.', 'Biological markers', 'CSF biomarker analysis.', 'For the Imabio3 study, CSF samples obtained by', 'lumbar puncture were processed with the same procedures described', 'previously18 to obtain CSF levels of total tau, phosphorylated tau at', 'threonine 181 (P-Tau) and amyloid-β peptide 1–42 (amyloid-β42) by using', 'enzyme-linked immunosorbent assay kits (Innogenetics), according to the', \"manufacturer's instructions. All the operators were masked to clinical\", 'information. CSF biomarkers were available for 36/48 AD patients, among', 'whom 20/25 were AD-MCI. Controls did not have lumbar punction for', 'ethical reasons.', '[C11]PiB PET imaging procedures.', 'For the Imabio3 study, PET imaging with', '[C11]PiB was performed in 19 control subjects and in 43/48 AD patients,', 'among whom 23/25 were AD-MCI. The method was the same as previously', 'described.17 In summary, a global cortical index was deﬁned by the mean', 'standard uptake value ratio (with the cerebellum as the reference region)', 'of the following cortical regions: (1) frontal cortex, by grouping the orbito-', 'frontal, polar prefrontal and dorsolateral cortex; (2) anterior cingulate;', '(3) medial cingulate; (4) posterior cingulate; (5) precuneus; (6) occipital', 'cortex, by grouping the calcarine cortex, occipital cortex and cuneus;', '(7) temporal cortex, by grouping the anterior and lateral temporal cortex;', '(8) hippocampus; and (9) parietal cortex, by grouping the inferior and', 'superior parietal cortex and the parietotemporal junction.', 'Measures of enlarged endosomes', 'PBMC isolation from blood samples:', 'For each participant, 10 ml', 'blood was collected in heparin-coated tubes (Vacutainer, Beckton-', 'Dickinson, Franklin Lakes, NJ, USA). Blood samples were diluted in one', 'volume of phosphate-buffered saline and PBMCs isolated by centrifugation', 'on a 1077 g ml − 1 ﬁcoll gradient (15 ml preﬁlled ﬁltered Leucosep PANCOLL', 'tubes, PAN Biotech, Aidenbach, Germany) following the manufacturer’s', 'instructions. After centrifugation, PBMCs were re-suspended in 200 μl of', 'reduced serum culture medium (Gibco OPTI-MEM) and incubated at 37 °C,', '5% CO2', 'for', '1 h,', 'then rinsed and', 'ﬁxed for', '12 min in', '4% cold', 'paraformaldehyde and rinsed in 10 ml phosphate-buffered saline.', 'Culture of ﬁbroblast:', 'Fibroblasts were grown directly on microscope', 'coverslips in 24-well plates, in DMEM supplemented with 10% FCS and', '100 μg ml − 1 penicillin+streptomycin, for 24 to 48 h. Cells were ﬁxed before', 'reaching conﬂuence in 4% cold paraformaldehyde for 15 min and rinsed', 'three times with phosphate-buffered saline. The number of passages was', 'between 3 and 12 at the time of analysis.', 'Immunocytochemistry:', 'Paraformaldehyde-ﬁxed', 'PBMCs', 'were', 'incu-', 'bated with 2% normal goat serum for 20 min and permeabilized 20 min', 'in Triton 0.1% X-100. For staining of EEA1, cells were re-suspended in 1:100', 'solution of Polyclonal antibody (Cell signalling, Rabbit-anti-Human #2411)', 'in 2% normal goat serum at 5 °C overnight. Cells were rinsed in phos-', 'phate-buffered', 'saline', 'twice', 'and', 'incubated', 'with', '1:500', 'Alexa-488®-', 'conjugated Goat-anti-Rabbit antibody (A-11034, Invitrogen) in 2% normal', 'goat serum, for 2 h at room temperature. Slides were mounted by', 'mixing 10 μl of re-suspended cells in 10 μl mounting medium (South-', 'ernBiotech, ﬂuoromount-G) and sealed after one night air drying at room', 'temperature.', 'For ﬁbroblasts, EEA1 immuno-staining was performed following the', 'same protocol directly on coverslips with an additional staining of nuclei', 'before the last wash using DAPI for 2.5 min. Mounting was performed by', 'applying coverslips upside down on a drop of mounting medium and', 'sealed after one night air drying at room temperature.', 'Confocal imaging:', 'Immunoﬂuorescent labelling was observed under', 'an upright confocal microscope (Olympus Fluoview Fv1000) using a × 63', '(NA 1.40) apochromatic objective. All PBMC images were performed at the', 'same magniﬁcation. (Voxel size for PBMC: XY = 0.073 μm, Z = 0.25 μm). Due', 'to the large size of ﬁbroblasts, we applied a lower magniﬁcation (Voxel', 'size: XY = 0.094 μm, Z = 0.25 μm). Approximately 20 cells per subject for', 'PBMCs and 15 cells per subject for ﬁbroblasts were chosen randomly on', 'the slides and scanned individually by deﬁning the upper and lower', 'Enlarged endosomes in blood cells in Alzheimer’s disease', 'F Corlier et al', '2', 'Translational Psychiatry (2015), 1 – 8', 'position of the scanning device and by ﬁxing the space between slides to', '250 nm (the actual depth of ﬁeld of the objective) to sample the whole cell', 'volume for subsequent three-dimensional image treatment.', 'Image analysis of the endosomes:', 'The three-dimensional recon-', 'structed images were analysed applying a wavelet-based detection', 'method19 implemented as a plugin spot detector in Icy software20', '(http://icy.bioimageanalysis.org.) as described earlier for the analysis of', 'cells from DS individuals.13 The size was expressed as the number of voxels', 'in the detection, and when needed, converted in cubic micrometres (μm3)', 'according to voxel size. Staining and image analysis were performed', 'blindly by the same operator to guarantee anonymous and unbiased', 'interventions at all levels of sample processing and to avoid inter-operator', 'variability.', 'Automated data processing:', 'Data', 'extraction', 'and', 'analysis', 'was', 'automatized using MATLAB version 8.3.0.73043 (R2014a). The function', 'selects relevant data in the single result ﬁles provided by Icy software for', 'each cell, and implements a concatenated database of all subjects by', 'classifying them automatically with respect to clinical information, relating', 'every single detected endosome to the cell, as well as to the individual and', 'his clinical information.', 'Statistical analysis', 'The statistical analysis was performed with MATLAB’s Statistics Toolbox', 'Version 9.0 (R2014a).', 'Comparison of the endosome number and mean volume per cell.', 'The', 'endosome numbers and mean volumes per cell of the three groups, that', 'is, the control group (23 patients, 459 cells), the MCI-AD group (25 patients,', '497 cells) and the AD group (23 patients, 455 cells) were compared with an', 'analysis of variance with a ﬁxed group effect and a random individual', 'effect. To normalize the distributions and to homogenize their variances,', 'the analysis of variance was performed on the logarithm of the mean', 'numbers and volumes.', 'Comparison of the mean endosome volume distribution between groups.', 'To compare the distributions of the endosome volumes per cell in the', 'three groups, we classiﬁed the mean volumes in size categories. The', 'distributions being heavily skewed to the right (overall skewness and', 'kurtosis of 2.7 and 16.6, respectively), we chose the median and ninth', 'decile of the control group volumes as the limits of three size categories', 'small, medium and large. The distributions of the mean endosome', 'volumes per cell in the three size categories of the three groups were then', 'compared with a χ2 test. Further χ2 tests were used to perform the three', 'two-by-two comparisons between groups, that is, controls/AD, controls/', 'MCI-AD and MCI-AD/AD; the P-values of the latter were adjusted for', 'multiple testing using the Bonferroni correction.', 'As the analysis of variance had shown a signiﬁcant individual effect on', 'the mean endosome volume per cell, we used bootstrap sampling at the', 'individual level (1000 samples were randomly drawn) to assess the stability', 'of the distributions across the size categories and of the signiﬁcance of the', 'difference between the distributions in the control and AD groups.', 'Correlation of the mean endosome volume with the clinical data.', 'Pearson’s', 'correlation was computed between the mean endosome volume of the', 'patients (MCI-AD and AD) and their amyloid load measured by PiB', 'retention. A generalized linear model was used to adjust for age and APOE', 'genotype.', 'RESULTS', 'Population demographics', 'Morphometric analyses of early endosomes (number and volume)', 'in PBMCs were obtained from 48 patients with AD (23 AD and 25', 'MCI-AD) and 23 healthy controls at inclusion (Table 1).', 'There were no signiﬁcant differences in sex and age across the', 'AD-MCI, AD-D and control groups. As expected, there were', 'signiﬁcant differences across the diagnostic groups (MCI-AD and', 'AD) for APOE ε4 status, amyloid burden and cognitive deﬁcits', '(MMSE and CDR) with AD and MCI-AD groups having more APOE', 'ε4 carriers and poorer performance on cognitive assessments as', 'compared with healthy controls. Individual data are presented as', 'Supplementary Material (Supplementary Table).', 'Table 1.', 'Demographic and clinical data of analysed groups', 'Controls', 'AD-MCI', 'AD-D', 'PBMC analysis', 'Number of individuals (N)', '23', '25', '23', 'Sex ratio (F/M)', '13/10', '14/11', '12/11', 'Age', '67 ± 10.39 (51–86)', '67.68 ± 9.7 (52–82)', '69.43 ± 11.6 (51–91)', 'MMSE', '29.9 ± 0.92 (27–30)', '23.7 ± 3.19 (18–30)', '15.43 ± 4.9 (4–22)', 'CDR = 0.5', '—', '25', '—', 'CDR = 1', '—', '—', '23', 'APOE ε4/ -', '2/23', '10/25', '7/23', 'ε4/ε4', '0/23', '7/25', '5/23', '[11]C-PIB PET scan', '20/23', '23/25', '20/23', 'Lumbar puncture', '—', '20/25', '16/23', 'Number of analysed cells', '454', '460', '427', '% Cells with small MEV', '50.1', '51.7', '46.8', '% Cells with medium MEV', '39.9', '34.8', '35.8', '% Cells with large MEV', '10.0', '13.5', '17.4', 'Fibroblast analysis', 'Number of individuals (N)', '5', '—', '6', 'Sex ratio (F/M)', '5/0', '—', '1/5', 'Age', '70.8 ± 8.01 (63–83)', '—', '78.5 ± 7.77 (69–88)', 'MMSE', '30', '18 ± 2.45 (16–21)', 'APOE ε4/ -', '0/5', '—', '2/6', 'ε4/ε4', '1/5', '—', '1/6', 'Number of analysed cells', '76', '90', '% Cells with small MEV', '50.0', '31.1', '% Cells with medium MEV', '39.5', '42.2', '% Cells with large MEV', '10.5', '26.7', 'Abbreviations: AD-D, Alzheimer’s disease with dementia; AD-MCI, Alzheimer’s disease with mild congnitive impairment; CDR, Clinical Dementia Rating; MEV,', 'mean endosome volume; MMSE, Mini Mental State Examination; PBMC, peripheral blood mononuclear cell; PET, positron emission tomography.', 'Enlarged endosomes in blood cells in Alzheimer’s disease', 'F Corlier et al', '3', 'Translational Psychiatry (2015), 1 – 8', 'Analysis of the mean endosome volume and number in PBMCs', 'The PBMCs from all patients with AD-D, AD-MCI and healthy', 'controls were puriﬁed from fresh blood, ﬁxed and their early', 'endosomes stained by immunocytochemistry using an antibody', 'against early endosome antigen 1 (EEA1). Z-stack images of ~ 20', 'cells for each individual were obtained under the confocal', 'microscope.', 'Figures 1a–c show representative images obtained from PBMCs', 'of control, AD-MCI and AD-D individuals. Videos of three-', 'dimensional', 'reconstructed', 'images', 'are', 'available', 'as', 'Supplementary Material (Supplementary Videos 1–3).', 'Endosomes present in the whole cell volume were detected', 'with the spot detector plugin of Icy software.20 Volumes of', 'individual endosomes were measured as voxels. A total of 459,', '497 and 455 cells were analysed in the healthy control, AD-MCI', 'and AD-D', 'groups,', 'respectively.', 'For', 'each', 'individual,', 'mean', 'endosome number (MEN) and mean endosome volume (MEV)', 'per cell were calculated. Figures 1d and e show boxplots of', 'individual values for the healthy controls, AD-MCI and AD-D cases.', 'Individual', 'data', 'are', 'presented', 'as', 'Supplementary', 'Material', '(Supplementary Table).', 'According to analysis of variance, MEN and MEV were not', 'signiﬁcantly different either between AD-MCI, AD-D and control', 'groups (Pgroup = 0.63 for MEN and 0.61 for MEV) or between AD', 'group (AD-MCI and AD-D) and controls. The MENs per cell', 'were 22.47 for the controls, 20.12 for the AD-MCI and 21.92 for the', 'AD-D. The MEVs per cell were 214.90, 214.81 and 233.83 voxels', 'corresponding to 0.286 and 0.311 μm3 in the control/AD-MCI and', 'AD-D groups, respectively.', 'To verify between-day variability of endosome size and number', 'measurements for a given subject, we analysed blood samples', 'drawn from the same individual with no cognitive decline at 1-', 'month interval. No signiﬁcant difference was found in MEV and', 'MEN (Student’s t-test, P = 0.29 and 0.17, respectively, data not', 'shown).', 'Analysis of the endosome size distribution', 'We then categorized the 459, 497 and 455 cells from the healthy', 'control, AD-MCI and AD-D groups, respectively, in three classes', 'according to their mean endosomal volume. Small, medium and', 'large were deﬁned as classes containing endosomes with mean', 'volume below the median (o0.256 μm3; small), between the', 'ninth decile and the median (0.256 to 0.412 μm3; medium) and', 'above the ninth decile (40.412 μm3; large) in the control group.', 'Figure 2a shows the percentage of cells with MEV of the three', 'classes for the three groups. A higher percentage of cells with', 'larger MEV were found in the AD groups (13.5 and 17.4% for the', 'AD-MCI and the AD-D, respectively) as compared controls (10.0%).', 'Endosome size distributions were signiﬁcantly different for the', 'AD-D and the control groups (Bonferroni corrected P = 6.4 10 − 3 of', 'χ2 test).', 'Figure 1.', 'Endosomal abnormalities are present in peripheral mononuclear blood cells (PBMCs) from individuals with AD-MCI and AD-D. (a–c)', 'Immunoﬂuorescence confocal images showing EEA1-labelled early endosomes in representative PBMCs from cognitively healthy subjects (a),', 'AD-MCI (b) and AD-D cases (c). Scale bar, 2 μm. Mean endosome volumes (MEVs) (d) and mean endosome numbers (MENs) (e) per PBMC are', 'not signiﬁcantly different between AD-D (455 cells), AD-MCI (497 cells) and controls (CT, 459 cells). Pgroup = 0.63 for MEN and 0.61 for MEV', 'according to analysis of variance. AD-D, Alzheimer’s disease with dementia; AD-MCI, Alzheimer’s disease with mild congnitive impairment.', 'Enlarged endosomes in blood cells in Alzheimer’s disease', 'F Corlier et al', '4', 'Translational Psychiatry (2015), 1 – 8', 'We conﬁrmed the stability of these size distributions by drawing', '1000 bootstrap samples at the individual level: the percentage of', 'cells with large MEV was signiﬁcantly higher in the AD groups as', 'compared with control individuals (Bonferroni corrected Po0.05)', 'in 98% of the bootstrap samples. Means and standard deviations', 'on the bootstrap samples are shown in Figure 2b. These data', 'suggest that the size distribution of endosome was distinct', 'between healthy controls and AD groups.', 'Analysis of samples from the same control individual drawn at', '1-month interval did not show any difference in the distribution of', 'mean endosomal volume (P = 0.12 of χ2 test, data not shown).', 'Correlation between the mean endosomal volume per cell and the', 'cortical amyloid burden assessed by [C11]PiB PET', 'We then wondered what could cause the increase in the', 'percentage of cells with bigger endosomes in the AD-MCI and', 'AD-D cases. Since Aβ levels and APOE ε4 status have been shown', 'to be associated with the increase in the size of early endosomes', 'observed in neurons from AD patients,9 we analysed the potential', 'correlation between amyloid burden, the APOE status and the', 'mean endosomal volumes in the AD groups.', 'Pearson’s correlations were used to test the level of overlap', 'between endosomal volume and global amyloid burden mea-', 'sured by [C11]PiB retention. We found a signiﬁcant positive', 'correlation between MEV and global amyloid burden in 43 AD-MCI', 'and AD-D patients (r = 0.415, P = 0.008 after adjustment for age', 'and APOE ε4; Figure 3). High correlation was found in the', 'precuneus, a region with greatest levels of amyloid load21', '(r = 0.402, P = 0.018 after adjustment for age and APOE ε4).', 'In addition, we found a positive correlation (0.88) between MEV', 'and the APOE ε4 status (0, 1 or 2 alleles), although this correlation', 'was below statistical signiﬁcance (0.16, data not shown). MEV was', 'also more strongly correlated to PiB retention (r = 0.682, P = 0.0001', 'as compared with r = 0.415, P = 0.008, see above) when we', 'analysed AD-MCI and AD-D APOE ε4 carriers only (28 individuals,', 'Figure 3, dots in red).', 'Finally, we did not ﬁnd any correlation between the MEV and', 'other parameters such as the levels of Aβ, tau or P-tau in the CSF,', 'age and sex (data not shown).', 'Analysis of the endosomal compartment in ﬁbroblasts from AD-D', 'individuals', 'To conﬁrm the presence of abnormally larger endosomes in', 'peripheral cells from AD patients, we analysed the endosomal', 'compartment of ﬁbroblasts isolated from six independent AD-D', 'patients (90 cells) and ﬁve age-matched controls (76 cells).', 'Figures 4a and b show representative images obtained from', 'ﬁbroblasts of control (a) and AD-D individuals (b). Instead of', 'reporting the number of endosomes per cell, which would be', 'biased by the particularly high variability of shape and size among', 'ﬁbroblasts, we compared the density of endosomes per cell, the', 'Figure 2.', 'Percentage of PBMCs containing enlarged endosomes is signiﬁcantly higher in AD-D as compared with control (CT) individuals. (a)', 'Classiﬁcation of cells in three subclasses according to their MEV (small/medium/large) and (b) mean percentages and standard deviations on', '1000 bootstrap samples drawn at the individual level. AD-D, Alzheimer’s disease with dementia; AD-MCI, Alzheimer’s disease with mild', 'congnitive impairment; MEV, mean endosome volume; PBMC, peripheral blood mononuclear cell.', 'Figure 3.', 'Correlation between mean endosomal volume in AD', 'patients (AD-MCI and AD-D) and their PiB retention. Black dots', 'correspond to non-APOE ε4 carriers and red dots to APOE ε4 carriers;', 'r = 0.682, P = 0.0001 and r = 0.415, P = 0.008 for all AD patients (black', 'and red dots) and APOE ε4 carriers only (red dots) after adjusting for', 'age and APOE ε4. AD-D, Alzheimer’s disease with dementia; AD-MCI,', 'Alzheimer’s disease with mild congnitive impairment; PiB, Pittsburgh', 'Compound B.', 'Enlarged endosomes in blood cells in Alzheimer’s disease', 'F Corlier et al', '5', 'Translational Psychiatry (2015), 1 – 8', 'number of endosomes per cell divided by its volume obtained by', 'calculating the convex hull of all endosomes. As for PBMCs,', 'neither the mean density nor the MEV was signiﬁcantly different', 'between AD-D and controls (Figures 4c and d).', 'We then categorized the 76 and 90 cells from the healthy', 'control and AD-D groups, respectively, in three classes according', 'to their mean endosomal volume. Small, medium and large were', 'deﬁned as classes containing endosomes with mean volume', 'below the median (o0.14 μm3; small), between the ninth decile', 'and the median (0.141 to 0.19 μm3; medium) and above the ninth', 'decile (40.191 μm3; large) in the control group. Figure 5 shows', 'the percentage of cells with MEV of the three classes: 50% small,', '39.5% medium and 10.5% large for the controls and 31.1% small,', '42.2%medium and 26.7% large for the AD-D. A signiﬁcantly higher', 'percentage of cells with larger MEV was found in the AD-D group', 'as compared with controls (χ2 test, P = 0.0094).', 'DISCUSSION', 'Previous studies which aimed at identifying blood biomarkers in', 'AD were based on large longitudinal cohorts using top down', 'approach.22 Here, we used a hypothesis-driven approach based on', 'a very well-deﬁned population of AD patients. We applied strict', 'inclusion criteria based on both positive clinical/cognitive and', 'pathophysiological markers (CSF biomarkers and [C11]PiB PET).', 'More importantly, all healthy controls had negative cortical [C11]', 'PiB retention, thus excluding presymptomatic AD. We focused our', 'research on the analysis of the endosomal compartment, a', 'putative cellular biomarker expected to be less sensitive to serum', 'components.', 'Across the three very well-deﬁned groups (AD-MCI, AD-D and', 'controls), we found a signiﬁcant increase in the percentage of cells', 'containing enlarged endosomes in AD patients as compared with', 'controls, even at an early stage of the disease (AD-MCI).', 'Figure 4.', 'Endosomal abnormalities are present in ﬁbroblasts from individuals with AD-D. Immunoﬂuorescence confocal images showing', 'EEA1-labelled early endosomes (green) in representative ﬁbroblasts from cognitively healthy subjects (a) and AD-D cases (b). Nuclei are', 'labelled in blue. Scale bar, 2 μm. (c) Mean endosome volumes per ﬁbroblast are not signiﬁcantly different between control (CT) individuals', '(0.147 ± 0.016 μm3) and AD-D patients (0.170 ± 0.034 μm3; Wilcoxon P = 0.18). (d) Comparison of the mean endosomal densities per ﬁbroblast', '(that is, portion of the cell volume occupied by endosomes) showed no signiﬁcant difference between control individuals (0.0249 ± 0.005) and', 'AD-D patients (0.0279 ± 0.006; Wilcoxon P = 0.46). AD-D, Alzheimer’s disease with dementia; EEA1, early endosome antigen 1.', 'Figure 5.', 'Percentage of ﬁbroblasts containing enlarged endosomes', 'is signiﬁcantly higher in AD-D as compared with control (CT)', 'individuals. Classiﬁcation of cells in three subclasses according to', 'their MEV (small/medium/large)', 'showed', 'signiﬁcantly elevated', 'percentage of cells with large MEV in AD-D patients and reduced', 'percentage of cells with small MEV (χ2 test, P = 0.0094). AD-D,', 'Alzheimer’s disease with dementia; MEV, mean endosome volume.', 'Enlarged endosomes in blood cells in Alzheimer’s disease', 'F Corlier et al', '6', 'Translational Psychiatry (2015), 1 – 8', 'Importantly, we conﬁrmed the presence of enlarged endo-', 'somes in ﬁbroblasts from another small cohort of AD-D patients', 'thus demonstrating the presence of endosomal abnormalities in a', 'second peripheral cell type.', 'These results support the recent line of evidence showing an', 'over-representation of genes involved in endocytosis as AD', 'genetic risk factors.23 It will be interesting in a next study to', 'include these genetic risk factors.', 'Enlarged', 'endosomes', 'have', 'been', 'previously', 'identiﬁed', 'in', 'neuronal cells of AD-D, AD-MCI and DS patients as well as in', 'peripheral cells from individuals with DS.9,12 Changes of the', 'endosomal compartment observed here in PBMCs were signiﬁ-', 'cantly correlated in the AD diagnostic groups with amyloid', 'burden assessed by PET using [C11]PiB retention. Notably, this', 'correlation was still valid after conditioning with age and APOE ε4', 'status. It thus appears that factors other than APOE ε4 allele and', 'age likely contribute to the change observed in the morphology of', 'early endosomes. Even though changes in the endosomal', 'compartment of neuronal cells appear speciﬁc of AD and DS,9 it', 'will be important to analyse the endosomal compartment of', 'peripheral cells in other types of neurodegenerative diseases than', 'AD or DS (present study and Cossec et al.13). At least no correlation', 'was found between MEV of PBMCs from AD patients and their age', 'suggesting that such changes in the endosomal compartment are', 'not correlated to age.', 'Aβ has been linked to endosomal dysfunctions in AD and DS.', 'Indeed enlarged endosomes in post-mortem brains of sporadic', 'AD and DS patients contain Aβ.9 However, enlarged endosomes', 'are present in DS brains before Aβ can be detected and conversely', 'enlarged endosomes are absent in familial AD brains with', 'mutations in presenilin1 overproducing Aβ.9 In DS ﬁbroblasts,', 'amyloid precursor protein C-terminal fragment (β-CTF) rather than', 'Aβ appeared to be related to endosomal dysfunction.24 It will be', 'interesting to compare the levels of β-CTF in ﬁbroblasts from', 'controls individuals and AD patients.', 'In PBMC from AD patients (MCI and D), we found that enlarged', 'endosomes are more strongly correlated to amyloid burden when', 'we stratiﬁed APOE ε4 carriers (Supplementary Figure 1). But since', 'this correlation in AD-D and AD-MCI was still valid after', 'conditioning with APOE genotype, the APOE genotype could', 'participate nonexclusively in the formation of enlarged endo-', 'somes in peripheral cells.', 'The', 'levels', 'of', 'plasma', 'APOE', 'may', 'be', 'important', 'for', 'the', 'endososomal function as APOE ε4 carriers have lower levels of', 'plasma APOE4 protein that could predispose them to AD.25', 'However, APOE genotype does not inﬂuence the metabolism of', 'plasma Aβ peptides in young persons without memory deﬁcits.26', 'In addition, APOE ε4- but not ε4+ AD participants showed positive', 'relationships between plasma Aβ1–40/Aβ1–42 and PiB uptake.27', 'Macrophages are able to cross the blood–brain barrier and', 'phagocytize cerebral Aβ while Aβ-engorged macrophages are', 'adherent and cannot cross the blood–brain barrier back into the', 'blood.28', 'We', 'were', 'unable', 'to', 'detect', 'Aβ', 'in', 'PBMCs', 'using', 'immunocytochemistry (data not shown). Thus, the role of', 'peripheral Aβ in enlarged endosomes found in PBMC remains', 'unclear.', 'PBMCs are blood cells with a round nucleus including 70–90%', 'lymphocytes (T cells, B cells and NK cells), 10–30% monocytes and', 'few percentage of macrophages and dendritic cells. The higher', 'percentage of PBMCs containing enlarged endosomes observed', 'in AD and AD-MCI compared with healthy controls could be the', 'result of either a change of the endosomal compartment in a', 'subpopulation of cells or a change in a small percentage of all cell', 'types. Additional experiments of co-labelling of large endosome', 'bearing cells with selective markers, or cell sorting using a panel of', 'antibodies including anti-EEA1 will be necessary to conﬁrm one of', 'these hypotheses. However, as ﬁbroblasts also carry this enlarged-', 'endosome phenotype, we believe that endosomal changes are', 'more likely to be present in a small percentage of all cell types of', 'PBMCs rather than in a speciﬁc subpopulation.', 'Inﬂammation could also be involved in endocytosis and the', 'morphological changes of endosomes. As inﬂammation is a', 'hallmark of AD and the neutrophil–lymphocyte ratio was shown', 'to be elevated in AD, it will be interesting to test the correlation', 'between endosomal volume and the neutrophil–lymphocyte', 'ratio.29', 'We showed previously that higher cholesterol levels at the', 'plasma membrane', 'of cultured', 'cells and', 'neurons', 'induced', 'enlargement of early endosomes and subsequent increase of', 'Aβ.30–32 It is also well admitted that cholesterol levels are', 'increased in AD brains notably in membranes as well as in amyloid', 'plaques.33–35 As neutral lipids have been found to be increased in', 'a very high percentage of PBMCs in AD (85% compared with 7% in', 'controls), and cholesterol-related genes are also differentially', 'expressed in PBMC, it remains possible that cholesterol home-', 'ostasis could be involved in endosome changes observed in', 'PBMCs in AD patients.36,37', 'Nevertheless, it will be interesting to know whether some of the', 'endolysosomal proteins that have been shown to be increased in', 'the CSF of AD patients, including EEA1, are also changed in PBMC', 'or plasma.15', 'In conclusion, in this study, we found morphological alterations', 'of the endosomal compartment in blood cells (PBMCs) from', 'sporadic biologically conﬁrmed AD patients as well as in', 'ﬁbroblasts of clinically deﬁned independent sporadic AD patients', 'that may reﬂect amyloid pathology in the brain and could thus be', 'a new peripheral and blood biomarker. Future studies will', 'determine whether changes in the endosomal compartment in', 'PBMCs and ﬁbroblasts from the same patients are equally', 'correlated to amyloid load, how they evolve during the time', 'course of the disease and whether endosomal biomarkers, either', 'cellular or plasmatic, can be identiﬁed.', 'CONFLICT OF INTEREST', 'The authors declare no conﬂict of interest.', 'ACKNOWLEDGMENTS', 'This study was supported by a grant from the French Ministry of Health (PHRC-0054-', 'N 2013) and Institut Roche de Recherche et Médecine Translationnelle. The research', 'leading to these results has received funding from the programme ‘Investissements', \"d'avenir’ ANR-10-IAIHU-06. Analysis by confocal microscopy was performed at the\", 'cellular imaging platform of Pitié-Salpêtrière. We are thankful to Christian Czech and', 'Tania Nikolcheva, representing Roche LA, for reviewing this work. We are greatly', 'indebted', 'to', 'the', 'chemical/radiopharmaceutical', 'and', 'nursing', 'staff', 'of', 'Service', 'Hospitalier Frédéric Joliot for the synthesis of the [C11]PiB and patient management', 'and gratefully acknowledge the team of CENIR (Centre de Neuroimagerie de', 'Recherche) from the Salpêtrière Hospital for patients management during MRI', 'acquisition. We also thank the CATI (Centre d’Acquisition et de Traitement d’Images),', 'a French national platform supported by the Alzheimer’s Foundation.', 'MEMBERS OF THE CLINICAL IMABIO3 TEAM', 'Dr', 'Amer', 'Alnajjar-Carpentier,', 'Consultation', 'mémoire,', 'Hôpital', 'd’Orsay, Orsay, France; Dr Michel Logak, Service de Neurologie,', 'Hôpital Saint Joseph, Paris, France; Dr Sara Leder and Dr', 'Dominique Marchal, Consultation mémoire, Institut des Invalides,', 'Paris, France; Dr Hélène Pitti-Ferandi, Consultation mémoire,', 'Clinique de la Porte Verte, Versailles, France; Dr Hélene Brugeilles,', 'Service de Neurologie, Hôpital Mignot, Versailles, France; Dr', 'Brigitte Roualdes, Service de Neurologie, Hopital Henri Mondor,', 'Versailles, France; Dr Agnes Michon, Consultation mémoire,', 'Hôpital de la Salpêtrière, Paris, France.', 'Enlarged endosomes in blood cells in Alzheimer’s disease', 'F Corlier et al', '7', 'Translational Psychiatry (2015), 1 – 8', 'REFERENCES', '1 Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P et al. Drug repo-', \"sitioning for Alzheimer's disease. Nat Rev Drug Discov 2012; 11: 833–846.\", '2 Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC et al. The', \"diagnosis of mild cognitive impairment due to Alzheimer's disease: recommen-\", \"dations from the National Institute on Aging-Alzheimer's Association workgroups\", \"on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:\", '270–279.', '3 Duyckaerts C, Delatour B, Potier MC. Classiﬁcation and basic pathology of', 'Alzheimer disease. Acta Neuropathol 2009; 118: 5–36.', '4 Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC et al. Clinical and', \"biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med\", '2012; 367: 795–804.', '5 Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other', 'neurodegenerative disorders. Ann Neurol 2011; 70: 532–540.', '6 Cataldo AM, Barnett JL, Berman SA, Li J, Quarless S, Bursztajn S et al. Gene', \"expression and cellular content of cathepsin D in Alzheimer's disease brain: evi-\", 'dence for early up-regulation of the endosomal-lysosomal system. Neuron 1995;', '14: 671–680.', '7 Cataldo AM, Barnett JL, Pieroni C, Nixon RA. Increased neuronal endocytosis and', \"protease delivery to early endosomes in sporadic Alzheimer's disease: neuro-\", 'pathologic evidence for a mechanism of increased beta-amyloidogenesis.', 'J Neurosci 1997; 17: 6142–6151.', '8 Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M et al.', 'Abeta localization in abnormal endosomes: association with earliest Abeta ele-', 'vations in AD and Down syndrome. Neurobiol Aging 2004; 25: 1263–1272.', '9 Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA.', 'Endocytic pathway abnormalities precede amyloid beta deposition in sporadic', \"Alzheimer's disease and Down syndrome: differential effects of APOE genotype\", 'and presenilin mutations. Am J Pathol 2000; 157: 277–286.', '10 Cataldo A, Rebeck GW, Ghetri B, Hulette C, Lippa C, Van Broeckhoven C et al.', \"Endocytic disturbances distinguish among subtypes of Alzheimer's disease and\", 'related disorders. Ann Neurol 2001; 50: 661–665.', '11 Coppus AM, Schuur M, Vergeer J, Janssens AC, Oostra BA, Verbeek MM et al.', \"Plasma beta amyloid and the risk of Alzheimer's disease in Down syndrome.\", 'Neurobiol Aging 2012; 33: 1988–1994.', '12 Cataldo AM, Mathews PM, Boiteau AB, Hassinger LC, Peterhoff CM, Jiang Y et al.', 'Down syndrome ﬁbroblast model of Alzheimer-related endosome pathology:', 'accelerated endocytosis promotes late endocytic defects. Am J Pathol 2008; 173:', '370–384.', '13 Cossec JC, Lavaur J, Berman DE, Rivals I, Hoischen A, Stora S et al. Trisomy for', 'Synaptojanin1 in Down syndrome is functionally linked to the enlargement of', 'early endosomes. Hum Mol Genet 2012; 21: 3156–3172.', '14 Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M et al. Genome-', 'wide association study identiﬁes variants at CLU and CR1 associated with', \"Alzheimer's disease. Nat Genet 2009; 41: 1094–1099.\", '15 Armstrong A, Mattsson N, Appelqvist H, Janefjord C, Sandin L, Agholme L et al.', \"Lysosomal network proteins as potential novel CSF biomarkers for Alzheimer's\", 'disease. Neuromol Med 2014; 16: 150–160.', '16 Koric L, Felician O, Ceccaldi M. [Use of CSF biomarkers in the diagnosis of', \"Alzheimer's disease in clinical practice]. Rev Neurol 2011; 167: 474–484.\", '17 de Souza LC, Corlier F, Habert MO, Uspenskaya O, Maroy R, Lamari F et al. Similar', \"amyloid-beta burden in posterior cortical atrophy and Alzheimer's disease. Brain\", '2011; 134(Pt 7): 2036–2043.', '18 de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R et al. Cerebrospinal', \"ﬂuid biomarkers in the differential diagnosis of Alzheimer's disease from other\", 'cortical dementias. J Neurol Neurosurg Psychiatry 2011; 82: 240–246.', '19 Olivo-Marin JC. Extraction of spots in biologicalimages using multiscale products.', 'Pattern Recogn 2002; 35: 1989–1996.', '20 de Chaumont F, Dallongeville S, Chenouard N, Herve N, Pop S, Provoost T et al.', 'Icy: an open bioimage informatics platform for extended reproducible research.', 'Nat Methods 2012; 9: 690–696.', '21 Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G et al. Imaging beta-', 'amyloid burden in aging and dementia. Neurology 2007; 68: 1718–1725.', '22 Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S et al.', \"Developing novel blood-based biomarkers for Alzheimer's disease. Alzheimers\", 'Dement 2014; 10: 109–114.', \"23 Karch CM, Goate AM. Alzheimer's disease risk genes and mechanisms of disease\", 'pathogenesis. Biol Psychiatry 2015; 77: 43–51.', '24 Jiang Y, Mullaney KA, Peterhoff CM, Che S, Schmidt SD, Boyer-Boiteau A et al.', \"Alzheimer's-related endosome dysfunction in Down syndrome is A{beta}-inde-\", 'pendent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci', 'USA 2009; 107: 1630–1635.', '25 Martinez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP et al. Total', 'apolipoprotein E levels and speciﬁc isoform composition in cerebrospinal ﬂuid', \"and plasma from Alzheimer's disease patients and controls. Acta Neuropathol\", '2014; 127: 633–643.', '26 Zimmermann R, Huber E, Schamber C, Lelental N, Mroczko B, Brandner S et al.', 'Plasma concentrations of the amyloid-beta peptides in young volunteers: the', 'inﬂuence of the APOE genotype. J Alzheimers Dis 2014; 40: 1055–1060.', '27 Swaminathan S, Risacher SL, Yoder KK, West JD, Shen L, Kim S et al. Association of', 'plasma and cortical amyloid beta is modulated by APOE epsilon4 status. Alzhei-', 'mers Dement 2014; 10: e9–e18.', '28 Zaghi', 'J,', 'Goldenson', 'B,', 'Inayathullah', 'M,', 'Lossinsky', 'AS,', 'Masoumi', 'A,', 'Avagyan H et al. Alzheimer disease macrophages shuttle amyloid-beta from', 'neurons to vessels, contributing to amyloid angiopathy. Acta Neuropathol 2009;', '117: 111–124.', '29 Rembach A, Watt AD, Wilson WJ, Rainey-Smith S, Ellis KA, Rowe CC et al. An', \"increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age\", 'and is weakly correlated with neocortical amyloid accumulation. J Neuroimmunol', '2014; 273: 65–71.', '30 Cossec JC, Marquer C, Panchal M, Lazar AN, Duyckaerts C, Potier MC. Cholesterol', \"changes in Alzheimer's disease: methods of analysis and impact on the formation\", 'of enlarged endosomes. Biochim Biophys Acta 2010; 1801: 839–845.', '31 Cossec JC, Simon A, Marquer C, Moldrich RX, Leterrier C, Rossier J et al.', 'Clathrin-dependent APP endocytosis and Abeta secretion are highly sensitive to', 'the level of plasma membrane cholesterol. Biochim Biophys Acta 2010; 1801:', '846–852.', '32 Marquer C, Devauges V, Cossec JC, Liot G, Lecart S, Saudou F et al. Local cho-', 'lesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts', 'and rapid endocytosis. FASEB J 2011; 25: 1295–1305.', '33 Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K et al. Involve-', 'ment of oxidative stress-induced abnormalities in ceramide and cholesterol', \"metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA 2004;\", '101: 2070–2075.', '34 Lazar AN, Bich C, Panchal M, Desbenoit N, Petit VW, Touboul D et al. Time-of-ﬂight', 'secondary ion mass spectrometry (TOF-SIMS) imaging reveals cholesterol over-', 'load in the cerebral cortex of Alzheimer disease patients. Acta Neuropathol 2012;', '125: 133–144.', '35 Panchal M, Loeper J, Cossec JC, Perruchini C, Lazar A, Pompon D et al. Enrichment', \"of cholesterol in microdissected Alzheimer's disease senile plaques as assessed by\", 'mass spectrometry. J Lipid Res 2010; 51: 598–605.', '36 Pani A, Mandas A, Diaz G, Abete C, Cocco PL, Angius F et al. Accumulation of', 'neutral lipids in peripheral blood mononuclear cells as a distinctive trait of', 'Alzheimer patients and asymptomatic subjects at risk of disease. BMC Med 2009;', '7: 66.', '37 Mandas A, Abete C, Putzu PF, la Colla P, Dessi S, Pani A. Changes in cholesterol', 'metabolism-related gene expression in peripheral blood mononuclear cells from', 'Alzheimer patients. Lipids Health Dis 2012; 11: 39.', 'This work is licensed under a Creative Commons Attribution 4.0', 'International License. The images or other third party material in this', 'article are included in the article’s Creative Commons license, unless indicated', 'otherwise in the credit line; if the material is not included under the Creative Commons', 'license, users will need to obtain permission from the license holder to reproduce the', 'material. To view a copy of this license, visit http://creativecommons.org/licenses/', 'by/4.0/', 'Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)', 'Enlarged endosomes in blood cells in Alzheimer’s disease', 'F Corlier et al', '8', 'Translational Psychiatry (2015), 1 – 8']\n"
     ]
    }
   ],
   "source": [
    "#This script returns UMLS CUIs based on an input file of strings, where each line in txt file is a separate string.\n",
    "#If no results are found for a specific string, this will be noted in output and output file.\n",
    "#Each set of results for a string is separated in the output file with '***'.\n",
    "\n",
    "\n",
    "import requests\n",
    "import argparse\n",
    "api_key = 'c6109e1b-7f0a-463f-9a11-1a5342006c1a'\n",
    "import requests\n",
    "\n",
    "# Set API key and other parameters\n",
    "api_key = 'c6109e1b-7f0a-463f-9a11-1a5342006c1a'\n",
    "version = 'current'\n",
    "outputfile = 'testing_output.txt'\n",
    "inputfile = 'tp201587a.txt'  # Change this to your actual input file\n",
    "sabs = None  # Example: 'MSH,SNOMEDCT_US,RXNORM'\n",
    "ttys = None  # Example: 'PT,SY,IN'\n",
    "\n",
    "base_uri = 'https://uts-ws.nlm.nih.gov'\n",
    "string_list = []\n",
    "\n",
    "# Read input file\n",
    "with open(inputfile, encoding='utf-8') as f:\n",
    "    for line in f:\n",
    "        if line.strip():  # Ignore empty lines\n",
    "            string_list.append(line.strip())\n",
    "\n",
    "print(\"Input strings:\", string_list)\n",
    "\n",
    "# Process each string\n",
    "with open(outputfile, 'w', encoding='utf-8') as o:\n",
    "    for string in string_list:\n",
    "        page = 0\n",
    "        o.write(f'SEARCH STRING: {string}\\n\\n')\n",
    "        \n",
    "        while True:\n",
    "            page += 1\n",
    "            path = f'/search/{version}'\n",
    "            query = {'string': string, 'apiKey': api_key, 'rootSource': sabs, 'termType': ttys, 'pageNumber': page}\n",
    "            output = requests.get(base_uri + path, params=query)\n",
    "            output.encoding = 'utf-8'\n",
    "            \n",
    "            output_json = output.json()\n",
    "            results = output_json.get('result', {}).get('results', [])\n",
    "            \n",
    "            if not results:\n",
    "                if page == 1:\n",
    "                    print(f'No results found for {string}\\n')\n",
    "                    o.write('No results found.\\n\\n')\n",
    "                break\n",
    "            \n",
    "            for item in results:\n",
    "                o.write(f\"UI: {item.get('ui', 'N/A')}\\n\")\n",
    "                o.write(f\"Name: {item.get('name', 'N/A')}\\n\")\n",
    "                o.write(f\"URI: {item.get('uri', 'N/A')}\\n\")\n",
    "                o.write(f\"Source Vocabulary: {item.get('rootSource', 'N/A')}\\n\\n\")\n",
    "            \n",
    "        o.write('***\\n\\n')\n",
    "\n",
    "print(f'Results saved to {outputfile}')\n"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.15"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
